Clinical Metric of Tumor Mutational Burden Depicts Colorectal Cancer Patients at the Extremes

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2025 Feb 21

PMID 39984774

Authors

Ming Zheng

Affiliations

Soon will be listed here.

Abstract

Purpose: Rare cases of colorectal cancer patients with exceptionally good or poor prognosis often remain overlooked, limiting insights into prognostic factors and underlying mechanisms.

Methods: This study developed an analytical framework to investigate cancer patients at the extremes using tumor mutational burden (TMB). By analyzing data from 1277 colorectal cancer patients who did not receive immunotherapy, this analysis assessed how patient survival varies with a broad range of TMB levels.

Results: Among patients with TMB ≤ 10 mutations per megabase (mut/Mb), increasing TMB was associated with worse survival outcomes. In contrast, patients with TMB > 10 mut/Mb showed increasingly improved survival. Notably, a small subgroup (3.83%) with TMB > 60 mut/Mb had significantly better survival outcomes.

Conclusions: These findings highlight TMB's dual role in colorectal cancer progression. This study suggests that atypical patients can coexist within the same "disease continuum" with typical patients, under the universal context unified by a shared cancer hallmark. TMB provides a useful biomarker for identifying these extremes, offering a clinical metric to better predict patient outcomes and personalize treatment strategies.

References

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Le D, Uram J, Wang H, Bartlett B, Kemberling H, Eyring A . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015; 372(26):2509-20. PMC: 4481136. DOI: 10.1056/NEJMoa1500596. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Le D, Durham J, Smith K, Wang H, Bartlett B, Aulakh L . Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017; 357(6349):409-413. PMC: 5576142. DOI: 10.1126/science.aan6733. View

Goodman A, Kato S, Bazhenova L, Patel S, Frampton G, Miller V . Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017; 16(11):2598-2608. PMC: 5670009. DOI: 10.1158/1535-7163.MCT-17-0386. View

Yarchoan M, Hopkins A, Jaffee E . Tumor Mutational Burden and Response Rate to PD-1 Inhibition. N Engl J Med. 2017; 377(25):2500-2501. PMC: 6549688. DOI: 10.1056/NEJMc1713444. View

Carbone D, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M . First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(25):2415-2426. PMC: 6487310. DOI: 10.1056/NEJMoa1613493. View

Hellmann M, Callahan M, Awad M, Calvo E, Ascierto P, Atmaca A . Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. Cancer Cell. 2018; 33(5):853-861.e4. PMC: 6750707. DOI: 10.1016/j.ccell.2018.04.001. View

10.

Miao D, Margolis C, Vokes N, Liu D, Taylor-Weiner A, Wankowicz S . Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018; 50(9):1271-1281. PMC: 6119118. DOI: 10.1038/s41588-018-0200-2. View

11.

Chan T, Yarchoan M, Jaffee E, Swanton C, Quezada S, Stenzinger A . Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2018; 30(1):44-56. PMC: 6336005. DOI: 10.1093/annonc/mdy495. View

12.

Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K . Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020; 21(10):1353-1365. DOI: 10.1016/S1470-2045(20)30445-9. View

13.

McGrail D, Pilie P, Rashid N, Voorwerk L, Slagter M, Kok M . High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 2021; 32(5):661-672. PMC: 8053682. DOI: 10.1016/j.annonc.2021.02.006. View

14.

Aggarwal C, Ben-Shachar R, Gao Y, Hyun S, Rivers Z, Epstein C . Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy. JAMA Netw Open. 2023; 6(5):e2311181. PMC: 10155064. DOI: 10.1001/jamanetworkopen.2023.11181. View

15.

Zheng M . Integrated profile of tumor stage and mutational burden predicts disparate clinical responses to immune checkpoint inhibitors: A risk-benefit study. Semin Oncol. 2024; 51(5-6):142-148. DOI: 10.1053/j.seminoncol.2024.08.003. View

16.

Valero C, Lee M, Hoen D, Wang J, Nadeem Z, Patel N . The association between tumor mutational burden and prognosis is dependent on treatment context. Nat Genet. 2021; 53(1):11-15. PMC: 7796993. DOI: 10.1038/s41588-020-00752-4. View

17.

Maleki Vareki S . High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors. J Immunother Cancer. 2018; 6(1):157. PMC: 6307306. DOI: 10.1186/s40425-018-0479-7. View

18.

Zheng M . Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better. J Immunother Cancer. 2022; 10(1). PMC: 8804687. DOI: 10.1136/jitc-2021-003087. View

19.

Crisafulli G, Sartore-Bianchi A, Lazzari L, Pietrantonio F, Amatu A, Macagno M . Temozolomide Treatment Alters Mismatch Repair and Boosts Mutational Burden in Tumor and Blood of Colorectal Cancer Patients. Cancer Discov. 2022; 12(7):1656-1675. PMC: 9394384. DOI: 10.1158/2159-8290.CD-21-1434. View